Skip to main content

Table 2 Clinicopathologic parameters of the patients and thrombocytosis

From: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Parameters

Thrombocytosis

P-value

Yes

No

Age

<56(427)

63(14.8 %)

364(85.2 %)

0.493

≥56(447)

58(13.0 %)

389(87.0 %)

FIGO Stage

Early(74)

3(4.1 %)

71(95.9 %)

0.008

Advanced(800)

118(14.8 %)

682(85.2 %)

CA125 Level

<500 U/ml(193)

15(7.8 %)

178(92.2 %)

0.004

≥500 U/ml(661)

103(15.6 %)

558(84.4 %)

Hyperfibrinogenemia

Yes (332)

77(23.2 %)

255(76.8 %)

<0.001

No (391)

15(3.8 %)

376(96.2 %)

Ascitesa

No (99)

3(3.0 %)

96(97.0 %)

<0.001

<500 ml(146)

5(3.4 %)

141(96.6 %)

≥500 ml(628)

113(18.0 %)

515(82.0 %)

Cytoreductionb

R0(271)

18(6.6 %)

253(93.4 %)

<0.001

R1(434)

67(15.4 %)

367(84.6 %)

R2(169)

36(21.3 %)

133(78.7 %)

Chemosensitivity

Yes (567)

69(12.2 %)

498(87.8 %)

0.043

No (237)

42(17.7 %)

195(82.3 %)

  1. aSubgroup analyses: PNo vs <500ml = 1.000, PNo vs >500ml < 0.001, P<500 ml vs <500ml < 0.001
  2. bSubgroup analyses: PR0 vs R1 = 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.092